Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK plus Metastatic NSCLC

被引：0

作者：

Dziadziuszko, Rafal ^{[1
]}

Kim, Dong-Wan ^{[2
]}

Bearz, Alessandra ^{[3
]}

Laurie, Scott ^{[4
]}

Mckeage, Mark ^{[5
]}

Park, Keunchil ^{[6
]}

Kim, Sang-We ^{[7
]}

Passos, Vanessa Q. ^{[8
]}

Osborne, Karen ^{[9
]}

Lau, Yvonne Y. ^{[8
]}

Gu, Jessie ^{[8
]}

Cho, Byoung Chul ^{[10
]}

机构：

[1] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Ctr Riferimento Oncol Ircc, Aviano, Italy

[4] Univ Ottawa, Med Oncol, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[5] Univ Auckland, Auckland, New Zealand

[6] Sungkyunkwan Univ, Sch Med, Div HEM ONC, Samsung Med Ctr, Seoul, South Korea

[7] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Novartis Pharma Ag, Basel, Switzerland

[10] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea

来源：

关键词：

Ceritinib; ALK; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a036

引用

页码：S1184 / S1184

页数：1